CA-ACCELERATED-BIOSCIEN
Accelerated Biosciences, a regenerative medicine innovator of proprietary human trophoblast stem cells (hTSCs), announced an agreement for Pluristyx, Inc., an advanced therapy tools and services biotechnology company, to provide iPSCs derived from hTSCs procured under Good Tissue Practices (GTP) for research evaluation.
Finding the ideal source of stem cells remains a challenge in cell and gene therapy. hTSCs overcome these challenges as they are ethically sourced, scalable, immune-privileged, pathogen-free, and chromosomally stable even at high population doublings. As Accelerated Biosciences’ CDMO partner, Pluristyx reprogrammed hTSCs to iPSCs with a footprint-free, proprietary mRNA method that yields highly pure stem cells with demonstrated capacity to form all three tissue types, including terminal differentiation into NK cells with superior cytolytic activity. hTSC-iPSCs are available in Pluristyx’s unique Ready-to-Differentiate® format (RTD®), allowing for rapid evaluation by eliminating the need for expansion out of thaw. Because hTSC-iPSCs are sourced under GTP, commercial partners can transition to a clinical-grade version when appropriate.
“We are thrilled to present our hTSC-iPSC platform as a new starting cell source for therapeutic companies. Our platform provides all of the business advantages and reduced risks. Clinical grade hTSC-iPSCs will be available in 2023 with a complete regulatory support package,” said Yuta Lee, Chief Executive Officer of Accelerated Biosciences.
“Pluristyx is excited to offer iPSCs derived from Accelerated Biosciences’ unique hTSC starting material. These iPSCs robustly form differentiated cells from all three lineages and are derived under GTP and they are not associated with any living human or embryo, making them an exceptional starting material for next generation cell-based therapies. Available in our RTD® format, interested groups can accelerate their internal evaluation and rapidly transition to a clinical-grade version suitable for therapeutic manufacturing,” said Benjamin Fryer, Chief Executive Officer of Pluristyx.
About Accelerated Biosciences
Accelerated Biosciences is a private regenerative medicine company commercializing the hTSC platform, discovered by physician and researcher, Professor Jau-Nan Lee, MB, MD, PhD. Accelerated Biosciences holds a proprietary source of hTSCs with a robust intellectual property estate. Accelerated Biosciences’ mission is to leverage its renewable, immune-privileged human cell source to accelerate cures to patients and to make gene and cell therapy affordable to all in need. For more information about Accelerated Biosciences, visit www.acceleratedbio.com or email mmolsbergen@c14consultinggroup.com .
About Pluristyx
Pluristyx is a privately held biotechnology company offering consulting, wet-lab and GMP banking services, and pluripotent stem cell products to support novel therapeutic developers. Pluristyx helps industry and academic researchers solve manufacturing and analytical challenges in cryopreservation, drug development, regenerative medicine, and cell and gene therapy. The Pluristyx team has decades of experience supporting every stage of cell therapy product development, from cell banking to drug product manufacturing including analytical testing and release of clinical grade cell therapy products. For more information about Pluristyx, visit www.pluristyx.com or email Kaye Reiter, PhD, JD at kreiter@pluristyx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005149/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hanshow and Delfi Partner to Expand Digital Solutions in Europe15.9.2025 10:04:00 CEST | Press release
Hanshow, a global leader in Electronic Shelf Labels (ESLs) and digital retail solutions, and Delfi Technologies, a Danish retail technology pioneer with decades of expertise in ESL platforms, today announced a new partnership, marking the start of closer cooperation to expand ESL offerings for retailers across Europe and accelerate the next phase of in-store digital transformation. Through this partnership, Delfi Technologies’ Breece System platform will be strengthened with Hanshow’s world-class ESL portfolio, proven in thousands of deployments worldwide. This partnership combines Delfi’s experience with ESL deployments in Europe and Hanshow’s global innovation leadership. Together, Hanshow will bring more flexibility, more options, and more value to retailers, helping them accelerate their digital transformation with lower costs and greater impact. The partnership also reinforces both companies’ commitment to sustainability. By replacing paper-based processes with digital price manag
SES Partners with Cailabs to Test Next-Generation Laser Communication Technology15.9.2025 10:00:00 CEST | Press release
Leading space solutions company will use optical ground stations to deliver faster, more secure data from space SES, a leading space solutions company, announced today it will test new optical ground stations built by France-based Cailabs to send data from space using laser beams instead of radio waves. By using optical communication, SES expects to be able to boost data transmission speeds, provide more secure links, and help alleviate congestion in increasingly crowded radio frequency bands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915922379/en/ SES Partners with Cailabs to Test Next-Generation Laser Communication Technology. Credit: Cailabs The partnership marks a major step forward for optical communications, which use light beams to transmit data at speeds of up to 10 gigabits per second—about 100 times faster than typical home internet. Unlike traditional radio signals, laser beams are nearly impossible to int
Prometheus Slashes Cost of Carbon Capture by More Than 80%, Unlocking Affordable E-Fuels as a New Source of 24/7 Carbon Neutral Power15.9.2025 10:00:00 CEST | Press release
Breakthrough reduces carbon capture costs to less than $50/ton—enabling fossil-price e-fuels to power AI, industry, and transportation at scale without subsidies or the grid Prometheus Fuels (Prometheus), the company producing low-cost carbon neutral fuels from direct air capture and renewable electricity, today announced it has achieved the lowest-cost carbon capture in the world, reducing the cost of Direct Air Capture (DAC) by more than 80 percent compared to industry averages. At under $50 per ton, Prometheus’ DAC cost breakthrough unlocks carbon neutral fuels at fossil fuel prices, without relying on subsidies, biogenic carbon, or point-source emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915079297/en/ Prometheus builds a 200-ton-per-year Direct Air Capture system at its California HQ, adding capacity to its currently operating 16-TPY system, the world’s lowest-cost DAC technology at less than $50 per ton
LSEG Launches Digital Markets Infrastructure Platform for Private Funds, and Facilitates First Transaction15.9.2025 09:25:00 CEST | Press release
LSEG today announces that it has launched its Digital Markets Infrastructure (“DMI”) platform for private funds and facilitated its first transaction. DMI, which is powered by Microsoft Azure, will deliver blockchain-powered scale and efficiencies for the full asset lifecycle – from issuance, tokenisation and distribution to post trade asset settlement and servicing, across multiple asset classes. LSEG will ensure that this platform is interoperable with current market solutions in distributed ledger technology as well as traditional finance, fully utilising a range of the group's products and services, including Workspace. Developed in collaboration with Microsoft, DMI is aligned with LSEG’s goal of being the first global exchange group to support customers across the full funding continuum, alongside other group initiatives such as the Private Securities Market. Private funds is the first asset class to benefit from the DMI platform, with expansion to additional asset classes planned
Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 202515.9.2025 09:15:00 CEST | Press release
The company will unveil Dexcom Smart Basal*, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark review.New Dexcom CGM data revealed at the conference will demonstrate how exercise before versus after meals can optimize glucose excursions in pregnant women with Type 1 diabetes.1 Additional findings will demonstrate how CGM can reduce neonatal complications linked to gestational diabetes more effectively than fingersticks.2Data presented at Dexcom’s symposium will reinforce that Dexcom CGM use reduced acute diabetes events.3 DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose biosensing technology for people with all types of diabetes at the upcoming 61st annual European Association for the Study of Diabetes (EASD) Conference. This press release features multimedia. Vi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom